2014
DOI: 10.2106/jbjs.cc.m.00254
|View full text |Cite
|
Sign up to set email alerts
|

Fibrocartilaginous Dysplasia of the Proximal Part of the Femur with a Pathological Fracture in a Child

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

0
6
0

Year Published

2021
2021
2022
2022

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(6 citation statements)
references
References 25 publications
(59 reference statements)
0
6
0
Order By: Relevance
“…The polyostotic variant usually is associated with McCune-Albright syndrome. 8,9 Our case was monostotic and did not have syndromic association.…”
Section: Discussionmentioning
confidence: 59%
See 1 more Smart Citation
“…The polyostotic variant usually is associated with McCune-Albright syndrome. 8,9 Our case was monostotic and did not have syndromic association.…”
Section: Discussionmentioning
confidence: 59%
“…3 A missense mutation in the guanine nucleotide binding protein/α subunit 1 gene on chromosome 20 causes FCD. 8,9 It is a genetic noninherited condition. The polyostotic variant usually is associated with McCune-Albright syndrome.…”
Section: Discussionmentioning
confidence: 99%
“…Another method in differential diagnosis is to show GNAS1 gene mutation localized on chromosome 20. It was reported that the GNAS1 mutation is found in 50-70% of FD cases, playing a role in pathogenesis of FD [2], which supports the diagnosis of FCD [12]. In fibroosseous lesions of the head and neck region, although there are few reported cases, GNAS1 mutations in FCM have not been demonstrated [18,19].…”
Section: Discussionmentioning
confidence: 95%
“…Eighteen cases were monostotic, 8 were polyostotic, with the most common location of the lesions in the proximal femur (80%). The most frequent symptoms are pain, swelling, deformity, pathological fracture, and limping, all of which have been reported [3][4][5][6][7][8][9][10][11][12][13][14][15]. In cases with clinical and follow-up data, symptom duration ranged from 8 weeks to 18 years (mean 62.2 months), with no recurrence or malignant transformation observed in mean follow-up of 21.71 (2-60) months after treatment.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation